Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.
IPO Year: 2020
Exchange: NASDAQ
Website: lanternpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $34.00 → $36.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $32.00 → $34.00 | Buy | HC Wainwright & Co. |
| 10/7/2021 | $32.00 | Buy | HC Wainwright & Co. |